Goldman Sachs has initiated coverage on Tempus AI (TEM.US) with a Neutral rating and a price target of $75. Based on the latest share price of $78.03, this implies approximately 4% downside. The assessment is not overly pessimistic—the near-term reimbursement catalysts for the diagnostics segment are quite tangible; however, contract renewals with major data clients cast a lingering question mark over the valuation.

The company, founded by Groupon co-founder Eric Lefkofsky and listed in 2024, builds its core narrative around connecting oncology genetic testing data with electronic health records, imaging, and follow-up outcomes, which it then sells to pharmaceutical companies. The two product lines—diagnostics and data—feed each other: higher testing volumes generate richer multimodal data, and richer data makes pharmaceutical companies more willing to pay while also providing better training material for algorithms. Goldman estimates diagnostics currently contribute roughly 75% of revenue, with data and applications accounting for about 25%. However, the latter serves as the anchor for the company's long-term strategy.

Diagnostics: The Reimbursement Window Is Opening

The most definitive near-term catalyst is xT. This companion diagnostic test for solid tumors has received FDA approval, allowing Tempus to migrate its entire solid tumor DNA product portfolio into a unified ADLT reimbursement framework. Management expects an average selling price increase of approximately $200, translating to roughly $85 million in annualized revenue starting in 2027. The key lies in the word "incremental": this builds on existing testing volumes without requiring major commercial reinvestment, making the margin impact more direct.

The larger growth opportunity lies in the xF liquid biopsy. This test has been submitted to the FDA, with Goldman projecting approval in the second half of 2027. If approved and eligible for ADLT pricing, reimbursement rates could rise from approximately $3,200 to roughly $7,500 currently, driving an average selling price increase of about $550. Combining xT and xF, management estimates approximately $400 million in incremental revenue could be unlocked by 2028. For a company with projected 2025 revenue of $1.272 billion and 2026 estimates of $1.593 billion, this represents a substantial opportunity.

Other initiatives in progress include: MRD testing momentum, which processed approximately 9,000 cases in 2Q26, up 38% quarter-over-quarter, although only about 10% to 15% of the sales team currently sells MRD—creating significant elasticity once reimbursement coverage expands; the recent launch of xH, a hematologic malignancy whole-genome sequencing test; and algorithm attach rates on oncology orders reaching approximately 45% in 2Q26. Additionally, Tempus has signed a definitive agreement to acquire Personaliis, a company with close ties to Moderna (MRNA.US) and Merck (MRK.US) personalized neoantigen therapy programs. Goldman has not included Personaliis revenue in its model, but notes that if intusmeran commercializes successfully, related testing volumes could reach approximately 60,000 cases by 2035.

Data: Contract Renewals Are the Litmus Test

The data story began earlier and is more complex. Tempus's Insights product licenses de-identified clinical, molecular, and imaging data to pharmaceutical companies, accounting for over 80% of the data segment. It has worked with 19 of the top 20 pharmaceutical companies and more than 250 biotech firms. Customer concentration is indeed declining: the top five clients' revenue share has dropped from 85% in 2020 to 59% in 2025. Over the next one to two years, several major contracts will enter renewal windows.

AstraZeneca (AZN.US) signed its MSA in November 2021 with a minimum spend of $220 million, extending through December 31, 2026, after which AstraZeneca can opt to add another $100 million and extend through 2028. GSK (GSK.US) signed its MSA originally in August 2022, amended in 2024, with a minimum spend of $180 million running through 2027, after which an additional $120 million can be added through 2030. Recursion (RXRX.US) signed its MSA in November 2023 with initial fees plus annual license fees totaling $160 million through 2028, though Recursion can terminate after November 2026 with 90 days' notice and a termination fee.

Goldman has not made a call on renewal outcomes, but highlights that investors will closely track these milestones. The rationale is straightforward: if major contracts renew successfully, Tempus's data segment "stickiness" and differentiation stand validated; any misstep would put pressure on the mid-teens growth guidance of 25%.

Moat: First-Mover Advantage Does Not Equal a Permanent Barrier

Tempus does hold a lead in multimodal data collection: generating data through its diagnostics business, establishing data pipelines with healthcare institutions, and collaborating with industry organizations. However, Goldman cautions that the company does not own the underlying EHR data. Its barrier partly stems from early investment—building data interfaces with hospital legal and IT teams requires time and capital—along with AI/ML capabilities that transform raw data into trainable model-ready datasets. The issue is that AI tools are advancing too rapidly, potentially shortening the time needed for later entrants to build similar pipelines.

Competition is converging from multiple directions. Diagnostics peers are increasingly emphasizing monetization of proprietary data: examples include Guardant Health (GH.US) with Infinity AI, Natera (NTRA.US) with its AI Foundation Models, and Caris (CAI.US) partnering with Flatiron. Roche (RHHBY.US) holds Flatiron's oncology EHR and Foundation Medicine's comprehensive tumor testing, naturally positioning it with a combined advantage. Goldman believes these competitors, if seeking to replicate Tempus's multimodal dataset, would likely need to partner directly with EHR systems or healthcare institutions; but now that Tempus has proven the business model viable, fast followers are unlikely to be scarce.

Tempus currently trades at roughly 8 times 2027 EV/Sales, which Goldman views as a discount to the peer median. The firm bases its valuation on approximately 7 times forward sales, arriving at the $75 price target. Financial models show the company generating projected 2026 revenue of $1.593 billion, 2027 revenue of $1.964 billion, and 2028 revenue of $2.373 billion; EBITDA is expected to climb from $98.2 million in 2026 to $237.5 million by 2028; EPS turns positive only by 2028 at an estimated $0.16.

In summary, Goldman balances the highly visible near-term growth prospects in the diagnostics segment against the uncertainty surrounding mid-term contract renewals in the data and applications division. The firm remains on the sidelines until gaining clearer visibility into these contract renewals and the evolving competitive landscape.